Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

Signal describes agents that block transcription factor activation

April 24, 1997

Phase III results for TS-110 in osteoarthritis

April 23, 1997

Caspase-1 involved in the regulation of multiple cytokines

April 21, 1997

Royce Laboratories' generic antiinflammatory approved by FDA

April 18, 1997

New MMP inhibitor disclosed by Agouron

April 18, 1997

New COX-2 inhibitor from Searle

April 15, 1997

Immunex's Enbrel demonstrates positive safety profile in RA patients

April 14, 1997

Wyeth-Ayerst and Elan develop new formulation of Lodine

April 11, 1997

NitroMed/J&J divisions collaborate on NSAID/NO donor compounds

April 9, 1997

Pivotal trial of Therafectin enrolled

April 3, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.